Aclaris Therapeutics, Inc. (ACRS) 10K Annual Reports & 10Q SEC Filings

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2022	Jan. 31, 2023	Jun. 30, 2022
Document and Entity Information
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-37581
Entity Registrant Name	Aclaris Therapeutics, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-0571712
Entity Address, Address Line One	640 Lee Road, Suite 200
Entity Address, City or Town	Wayne
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19087
City Area Code	484
Local Phone Number	324-7933
Title of 12(b) Security	Common Stock, $0.00001 par value
Trading Symbol	ACRS
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Fin Stmt Error Correction Flag	false
Document Fin Stmt Restatement Recovery Analysis Flag	false
Entity Shell Company	false
Entity Public Float			$ 898.4
Entity Common Stock, Shares Outstanding		66,692,964
Entity Central Index Key	0001557746
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Auditor Name	PricewaterhouseCoopers LLP
Auditor Firm ID	238
Auditor Location	Philadelphia, Pennsylvania
Amendment Flag	false

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1557746/000155837023001829/acrs-20221231x10k.htm

View differences made from one year to another to evaluate Aclaris Therapeutics, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Aclaris Therapeutics, Inc..

Continue

Assess how Aclaris Therapeutics, Inc.'s management team is paid from their Annual Proxy

Aclaris Therapeutics, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Rating
Learn More

Filter Sentiment:

All

Positive

Negative

Filter Category:

All

Financial

Revenue

M & A

Legal

Other

Filter Subcategory:

All

Cash Flow

Expense

Product

Geography

Income

Other

Inside Aclaris Therapeutics, Inc.'s 10-K Annual Report:

Financial - Cash Flow Highlight
Investing Activities Cash flow related to investing activities was the result of: The change in net cash provided by investing activities for the year ended December 31, 2022 compared to net cash used in investing activities for the year ended December 31, 2021 primarily resulted from higher sales and maturities of marketable securities during the year ended December 31, 2022, which were used to fund our operations, and a reduction of purchases of marketable securities, which were higher during the year ended December 31, 2021 following our January 2021 and June 2021 public offerings.

Financial - Expense Highlight
Research and Development The following table summarizes our research and development expenses by drug candidate or, for unallocated expenses, by type: Zunsemetinib The increase in expenses for zunsemetinib during the year ended December 31, 2022 compared to the year ended December 31, 2021 was primarily due to costs associated with clinical development activities for a Phase 2b trial in subjects with rheumatoid arthritis, which initiated in December 2021, a Phase 2a trial in subjects with hidradenitis suppurativa, which initiated in December 2021, a Phase 2a trial in subjects with psoriatic arthritis, which initiated in June 2022, and several ancillary clinical trials.
Other - Other Highlight
Upon execution of the agreement, we received $17.6 million from Lilly, a portion of which represented payments for regulatory and commercial milestones that were deemed to have been achieved as of the execution of the license agreement.
Financial - Expense Highlight
Facility and support services Facility and support services, including general office expenses, information technology costs and other expenses, increased during the year ended December 31, 2022 compared to the year ended December 31, 2021 primarily due to an increase in overhead expenses, including increases in tax and license fees and information technology support costs.
Financial - Shares Highlight
Upon execution of the agreement, we received an upfront payment of $5.0 million from Pediatrix, a portion of which was payable to the former Confluence equity holders as described above.
Financial - Expense
General and administrative expenses also...Read more
Financial - Expense
The effect of any change...Read more
Revenue - Product
Contract Research ? Contract research...Read more
Financial - Expense
ATI-1777 ? The increase in...Read more
Financial - Expense
ATI-2138 ? Expenses for ATI-2138...Read more
Revenue - Geography
For example, macroeconomic events, including...Read more
Financial - Expense
In addition, the Sarbanes-Oxley Act...Read more
Financial - Shares
Equity Purchase Agreement with Lincoln...Read more
Revenue - Product
Additionally, the inclusion of estimated...Read more
Other - Other
For example, if the FDA...Read more
Revenue - Product
Sale of Common Stock under...Read more
Other - Other
In addition, to the extent...Read more
Revenue - Product
Additionally, the inclusion of estimated...Read more
Financial - Shares
Upon execution of the Purchase...Read more
Financial - Income
Other income (expense), net primarily...Read more
Other - Other
The risk-free interest rate is...Read more
Other - Other
We may also not be...Read more
Other - Other
Any such changes could have...Read more
Financial - Income
Other income (expense), net increased...Read more
M & A - Other
Agreement and Plan of Merger...Read more
Legal - Other
Professional and legal fees ?...Read more
Financial - Shares
The commitment shares were valued...Read more
Financial - Expense
ATI-2231 ? Expenses for ATI-2231...Read more
M & A - Other
Our indefinite-lived intangible assets consist...Read more
Financial - Cash Flow
The fair value of an...Read more
Other - Other
In November 2018, the Financial...Read more
Revenue - Product
Contract research revenue is generally...Read more
M & A - Other
We initially recorded a contingent...Read more
Other - Other
Factors that could cause or...Read more
Financial - Shares
A portion of consideration received...Read more
Financial - Cash Flow
Since our inception, we have...Read more
Financial - Expense
Personnel and stock-based compensation ?...Read more
Revenue - Product
We may not be able...Read more
Other - Other
The decrease in non-cash adjustments...Read more
Other - Other
Definite-lived intangible assets are amortized...Read more
Financial - Expense
Our primary uses of capital...Read more
Other - Other
Our intangible assets include both...Read more
M & A - Other
Our definite-lived intangible assets consist...Read more
Other - Other
Indefinite-lived intangible assets are tested...Read more
Financial - Expense
For performance-based awards, we recognize...Read more
Financial - Expense
Licensing ? We incurred licensing...Read more
Other - Other
For further discussion of the...Read more

Financial Statements, Disclosures and Schedules

Inside this 10-K Annual Report

Material Contracts, Statements, Certifications & more

Aclaris Therapeutics, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 10.12: Material Contract

Exhibit 10.16: Material Contract

Exhibit 10.18: Material Contract

Exhibit 10.19: Material Contract

Exhibit 10.23: Material Contract

Exhibit 10.24: Material Contract

Exhibit 21.1: Subsidaries Of The Registrant

Exhibit 23.1: Consents Of Experts And Counsel

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Ticker: ACRS
CIK: 1557746
Form Type: 10-K Annual Report
Accession Number: 0001558370-23-001829
Submitted to the SEC: Thu Feb 23 2023 7:30:49 AM EST
Accepted by the SEC: Thu Feb 23 2023
Period: Saturday, December 31, 2022
Industry: Pharmaceutical Preparations

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/acrs/0001558370-23-001829.htm

Aclaris Therapeutics, Inc. (ACRS) SEC Filing 10-K Annual Report for the fiscal year ending Saturday, December 31, 2022

SEC Filings

ACRS Valuations

ACRS Annual Reports

ACRS Quarterly Reports

ACRS Corporate News